Indianapolis, Indiana, United States, November 10, 2026
Eli Lilly and Company has announced the launch of a new patient-focused campaign, Life Doesn’t Slow Down, featuring comedian and Foundayo™ (orforglipron) patient Leanne Morgan. The campaign aims to encourage conversations about obesity, weight management and available prescription treatment options, highlighting the importance of consulting healthcare professionals when lifestyle changes alone may not achieve desired weight-management goals. Through this initiative, Lilly is bringing greater attention to Foundayo, its once-daily oral GLP-1 prescription medicine, which is approved for chronic weight management in eligible adults with obesity or overweight accompanied by certain weight-related medical conditions. The campaign reflects the company’s efforts to make discussions about weight and healthcare more accessible while emphasizing the role of medical guidance in managing obesity.
Leanne Morgan Shares Her Weight-Management Experience
The Life Doesn’t Slow Down campaign features Leanne Morgan, who shares her personal experience of managing weight while balancing family responsibilities and a demanding professional career. According to the announcement, Morgan spent years attempting to manage her weight through diet and exercise alone. After recognizing that these approaches were not sufficient for her individual needs, she decided to discuss additional treatment options with her healthcare provider. Following that consultation, she and her doctor determined that Foundayo was an appropriate option for her. Morgan explained that the medication has become part of her daily routine alongside dietary changes and physical activity. As a paid spokesperson and patient partner for Lilly, she encourages individuals experiencing similar challenges to discuss weight-management options with their doctors. The company also emphasizes that her experience is personal and that individual treatment outcomes may vary. Through her involvement, Lilly aims to address the social and personal difficulties associated with discussing obesity and seeking medical support.
Foundayo Demonstrates Weight-Loss Results in Clinical Studies
Foundayo contains orforglipron, an orally administered, small-molecule GLP-1 receptor agonist designed to support chronic weight management. Unlike injectable GLP-1 treatments, this medicine is administered as a tablet once daily, with or without food. It is prescribed alongside a reduced-calorie diet and increased physical activity to help eligible adults lose excess body weight and maintain weight reduction. Lilly reported that clinical studies demonstrated meaningful weight-loss outcomes among participants receiving the medicine. In a 72-week study involving adults without diabetes, participants receiving the highest 17.2 mg dose experienced an average weight reduction of 11.1%, equivalent to approximately 24.9 pounds, compared with 2.1% among participants receiving placebo. In another 72-week study involving adults with type 2 diabetes, the highest-dose group achieved an average weight reduction of 9.6%, compared with 2.5% in the placebo group. These findings highlight the potential of oral GLP-1 therapies as an additional treatment option for eligible people managing obesity. Foundayo received U.S. Food and Drug Administration (FDA) approval in April 2026, becoming Lilly’s second medicine for chronic weight management.
Advertisement
Patient Access, Safety and Healthcare Provider Guidance
Lilly stated that Foundayo is available through several distribution channels in the United States, including LillyDirect home delivery, retail pharmacies and telehealth providers. The company has also outlined different payment options for eligible patients, including commercial insurance savings programs, self-pay arrangements and a Medicare GLP-1 Bridge program. These initiatives are intended to support access to prescription treatment for eligible individuals. However, patient eligibility, insurance coverage and program conditions apply. Alongside access information, the company highlights important safety considerations associated with Foundayo. The medicine should not be used with other GLP-1 receptor agonist medicines and is not approved for children. Its warnings include a potential risk of thyroid tumors, including thyroid cancer, and it should not be used by individuals with certain thyroid cancer histories or Multiple Endocrine Neoplasia syndrome type 2. Other reported adverse reactions include nausea, constipation, diarrhea, vomiting, abdominal discomfort, indigestion and headache. Healthcare professionals should evaluate individual medical histories, existing medications and potential risks before recommending treatment. Lilly also emphasizes that Foundayo is a prescription medicine intended for medical weight management rather than cosmetic weight loss. The launch of Life Doesn’t Slow Down demonstrates Lilly’s broader efforts to increase awareness of obesity as a health condition and encourage informed discussions between patients and healthcare providers. By combining patient storytelling with information about an approved oral treatment, the company is seeking to reduce hesitation around discussing weight-management challenges. Foundayo’s clinical results, oral administration and patient-access initiatives contribute to the evolving pharmaceutical landscape for obesity treatment. The campaign also reinforces the importance of combining appropriate prescription medicines with lifestyle modifications and professional medical supervision. As demand for effective obesity treatments continues to grow, Lilly’s initiative highlights the role of patient education and healthcare partnerships in supporting long-term weight-management strategies.
Source: Eli Lilly press release
